Mavrilimumab well tolerated among patients with RA

06:30 EST 15 Feb 2018 | Healio

Gerd R. Burmester
Mavrilimumab treatment for more than 3 years maintained response and was well-tolerated among patients with rheumatoid arthritis, with no increase in the prevalence of associated adverse effects, according to findings published in Arthritis and Rheumatology.
“Mavrilimumab is a human monoclonal antibody that blocks the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha, acting as a competitive antagonist of GM-CSF signaling,” Gerd R. Burmester, MD, of the University Medicine Berlin, told Healio Rheumatology. “It has previously

Original Article: Mavrilimumab well tolerated among patients with RA


More From BioPortfolio on "Mavrilimumab well tolerated among patients with RA"

Quick Search


Relevant Topics

Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....